Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Natl Cancer Inst ; 114(8): 1059-1064, 2022 08 08.
Article in English | MEDLINE | ID: mdl-35552713

ABSTRACT

This commentary discusses improving research advocacy as part of National Cancer Institute (NCI) clinical trial activities in scientific steering committees and task forces between 2016 and 2020. Before 2016, the focus of patient advocate input on clinical trial concept evaluation was assessing accrual feasibility. By leveraging informal benchmarking and an outside-in perspective, the NCI patient advocate steering committee, comprised of NCI scientific steering committee and task force advocates, has recalibrated research advocacy within and across its clinical trial concepts. Additionally, by focusing on research advocacy fundamentals, the NCI patient advocate steering committee clarified the scope of the research advocate roles, focused its mission, defined and developed competencies, measured engagement, and created collateral and processes that support better interactions and greater value generation. Continuous improvement in the collateral and the underlying approaches, along with calibrating their application and monitoring results, will be necessary to keep pace with the science and further enhance the value of cancer clinical trial research advocacy. The road ahead should build on these fundamentals and include increased emphasis on diversity, equity, and inclusion in clinical trial and research advocacy participants and the supporting infrastructure.


Subject(s)
Advisory Committees , Patient Advocacy , Humans , National Cancer Institute (U.S.) , United States
2.
Cardiology ; 120(3): 174-81, 2011.
Article in English | MEDLINE | ID: mdl-22261892

ABSTRACT

OBJECTIVE: It was the aim of this study to document the risks of symptomatic patients with angina in placebo-controlled, anti-anginal drug development trials in which symptom-limited exercise testing was used as the primary endpoint. PATIENTS AND METHODS: The original case report forms submitted to the United States Food and Drug Administration in support of approval of new or supplemental new drug applications between 1973 and 2001 were identified and subjected to a by-patient meta-analysis, utilizing both a maximum likelihood analysis and classical Mantel-Haenszel methods. RESULTS: There were 63 placebo-controlled, clinical trials that randomized 10,865 patients, with 1,047 patient-years of observation time. The trials involved 21 different chemical entities from 4 different drug classes. The relative risk (RR) for withdrawal (placebo compared to drug-treated patients) was not increased [RR = 0.92, 95% confidence interval (CI) 0.78-1.08; p = 0.28]. Of interest, a RR of 0.54 (95% CI 0.26-1.04; p < 0.068) for irreversible harm (a combination of cerebrovascular accidents, myocardial infarction and death) and a RR of 0.89 (95% CI 0.61-1.30; p = 0.56) for serious cardiovascular events (myocardial infarction, congestive heart failure, cerebrovascular accidents) both non-statistically significantly favored being randomized to placebo. CONCLUSIONS: For the development of current or future drugs for the treatment of angina, there is no obvious contraindication to the use of placebo controls and exercise tolerance testing.


Subject(s)
Angina Pectoris/drug therapy , Patient Safety , Placebos/adverse effects , Randomized Controlled Trials as Topic/adverse effects , Acetanilides/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Angina, Unstable/drug therapy , Calcium Channel Blockers/therapeutic use , Cardiovascular Diseases/chemically induced , Drug Approval , Enzyme Inhibitors/therapeutic use , Female , Hospitalization/statistics & numerical data , Humans , Male , Medical Records/statistics & numerical data , Middle Aged , Nitrates/therapeutic use , Observer Variation , Patient Dropouts/statistics & numerical data , Piperazines/therapeutic use , Ranolazine , Risk Assessment/methods , Risk Factors , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...